Showing results (51-60 of 118) with videos related to
Sort By:
Pageof 12
Nuclear Medicine and Biology|November 17, 2001
Cellular accumulation and retention of the technetium-99m-labelled hypoxia markers BRU59-21 and butylene amine oximeX Zhang, T Melo, A M Rauth, et al.Magnetic Resonance in Medicine|April 1, 1995
Susceptibility artifact reduction in fat suppressionJ Mao, J H Gao, H Yan, et al.International Journal of Radiation Oncology, Biology, Physics|December 9, 1998
Studies of 99mTc-BnAO (HL-91): a non-nitroaromatic compound for hypoxic cell detectionX Zhang, T Melo, J R Ballinger, et al.Annals of Nuclear Medicine|May 1, 1997
Accumulation of 99mTc-HMPAO and 99mTc-ECD in rodent and human breast tumor cell lines in vitroJ R Ballinger, J Duncan, H A Hua, et al.Journal of Pharmaceutical Sciences|May 29, 2000
Synthesis and characterization of surface-hydrophobic ion-exchange microspheres and the effect of coating on drug release rateZ Liu, X Y Wu, J R Ballinger, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 27, 2000
BRU59-21, a second-generation 99mTc-labeled 2-nitroimidazole for imaging hypoxia in tumorsT Melo, J Duncan, J R Ballinger, et al.Leukemia & Lymphoma|August 23, 2000
Accumulation of sestamibi in lymphoma cell lines in vitroM Kim, M V Gronda, H A Messner, et al.Magnetic Resonance Imaging|January 1, 1993
Mechanisms that contribute to the in vitro relaxation and signal intensity of water in barium sulfate suspensions used as MRI contrast agentsR W Briggs, T Liebig, J R Ballinger, et al.Bioconjugate Chemistry|September 30, 1999
Convenient preparation of no-carrier-added technetium-99m radiopharmaceuticals using solid-phase technologyR Dunn-Dufault, A Pollak, J R Thornback, et al.Biochemical Pharmacology|October 6, 1997
Modifying the in vitro accumulation of BMS181321, a technetium-99m-nitroimidazole, with unlabelled nitroaromaticsT Melo, H A Hua, J R Ballinger, et al.Pageof 12